Interplay of Genetic Risk Factors ( <i>CHRNA5</i> - <i>CHRNA3</i> - <i>CHRNB4</i> ) and Cessation Treatments in Smoking Cessation Success

Abstract

Smokers with the high-risk haplotype were three times as likely to respond to pharmacologic cessation treatments as were smokers with the low-risk haplotype. The high-risk haplotype increased the risk of cessation failure, and this increased risk was ameliorated by cessation pharmacotherapy. By identifying a high-risk genetic group with heightened response to smoking cessation pharmacotherapy, this work may support the development of personalized cessation treatments.